Reactions 1680, p69 - 2 Dec 2017 Endophthalmitis following an off label use: case report In a retrospective study, one patient was described [age and sex not stated], who developed endophthalmitis following an off-label treatment with bevacizumab [Avastin]. The patient was started on intravitreal bevacizumab injection PRN as an off‑label therapy for an unspecified ocular condition [dose not stated]. However, following bevacizumab administration, the patient developed endophthalmitis, which was considered to be related with bevacizumab [duration of treatment to reaction onset and outcome not stated]. Subsequently, the patient underwent vitrectomy. Author comment: "Ocular adverse drug reactions (ADRs) noted in the study group that were given injections included three patients who developed endophthalmitis". "Of the three patients with endophthalmitis, two responded to intravitreal antibiotics alone whereas one underwent vitrectomy." "The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions." Jain P, et al. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian Journal of Ophthalmology 65: 596-602, No. 7, Jul 2017. Available from: URL: http://doi.org/10.4103/ijo.IJO_992_16 - India 803285034 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera